KHẢO SÁT BIẾN CỐ ĐỘC TÍNH THẬN TRÊN CÁC BỆNH NHÂN ĐƯỢC CHỈ ĐỊNH COLISTIN TẠI BỆNH VIỆN E

Abstract

Objectives: Evaluate the characteristics and the potential risk factors of nephrotoxicity in colistin-treated patients at E hospital. Study  population  and  methods: A descriptive cross-sectional study was performed on 61 medical records of patients using colistin from January 2021 to December 2021 at E hospital. Results: All patients were checked for blood creatinine during the first 4-5 days of colistin administration, then the frequency rapidly dropped; by day 24, only 2% of patients received tests for creatinine. We identified 18/61 individuals (29.5%) who experienced acute nephrotoxicity as a result of colistin usage, with the degree of risk nephrotoxicity (27.8%), damage (44.4%), and renal failure (27.8%), and a median duration of nephrotoxicity of 9 days. The probability of nephrotoxicity in colistin patients increases over time. The following indicators have a statistically significant link with the probability of nephrotoxicity: age, reduced serum albumin, length of colistin therapy, and concomitant usage of furosemid. Conclusion: Nephrotoxicity is a challenge in colistin-treated patients, particularly those who are older, have a long history of colistin usage, and have concomitant diseases such as elevated blood bilirubin and reduced serum albumin. It, therefore, demonstrates the necessity for measures to prescribe medications and modify the dose correctly, customized based on renal function, in order to reduce the risk of nephrotoxicity and the efficacy of therapy for patients.